CFDA Said Considering Shortening Oncology Drug INDs To 60 Days
This article was originally published in The Pink Sheet Daily
China's FDA is acting swiftly to accelerate new drug approvals, this time with a focus on cancer. It is said to be planning a pilot scheme to change the investigational new drug process from an approval to a filing mechanism, and set 60 days as the timeframe.
Register for our free email digests: